Report cover image

Retinal Gene Therapy Market Report 2024-2034

Publisher Visiongain
Published Jul 26, 2024
Length 235 Pages
SKU # VSG19023890

Description

Retinal Gene Therapy Market Report 2024-2034



The Retinal Gene Therapy Market Report 2024-2034: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Increasing Prevalence of Inherited Retinal Diseases, Clinical Trial Success and Approvals Driving Market Growth

Some of the key factors driving the retinal gene therapy market growth include increasing prevalence of inherited retinal diseases, success of the clinical trials & approvals, and advancements in gene therapy technologies. Inherited retinal diseases though small in concentration have been increasingly identified across regions. Therefore, growing prevalence of IRDs, including as retinitis pigmentosa (RP) and Leber congenital amaurosis (LCA) has led to the demand for effective therapies. In addition to this, gene therapy technology has been proving to be effective method for number of conditions including ocular diseases. Also, with significant players including clinical trial companies have witnessed success in the product development and having strong product pipeline is likely to boost the adoption of the gene therapy practices for retinal diseases. There have been continuous efforts including vector design, gene editing, non-invasive route of administration, and others have promised safety and efficacy of retinal gene therapy technology.

On the other hand, with success of the clinical trials, there has been significant investments from government and private stakeholders in research & development activities for retinal gene therapy. This will be very critical development in terms of continuous efforts towards development of effective gene therapies for rare retinal diseases.

Limited Treatment Reach and High Cost Likely to Hamper Industry Growth

As of now retinal gene therapy has been restricted to limited centres around the world that are effectively engaging in the gene therapy practices. The therapy has been gaining wider recognition in developed regions including North America and Europe. Therefore, this therapy has long strides to cover in terms of the adoption, development of expertise, and infrastructure. Also, the cost of retinal gene therapy is on the higher side considerably with patented products and initial phase of the product life cycle. Therefore, easy patient access to this novel therapy is difficult on the current scenario. This is subjected to change with wider recognition and insurance coverage for the treatment.

What Questions Should You Ask before Buying a Market Research Report?
  • How is the retinal gene therapy market evolving?
  • What is driving and restraining the retinal gene therapy market?
  • How will each retinal gene therapy submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2034?
  • How will the market shares for each retinal gene therapy submarket develop from 2024 to 2034?
  • What will be the main driver for the overall market from 2024 to 2034?
  • Will leading retinal gene therapy markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
  • How will the market shares of the national markets change by 2034 and which geographical region will lead the market in 2034?
  • Who are the leading players and what are their prospects over the forecast period?
  • What are the retinal gene therapy projects for these leading companies?
  • How will the industry evolve during the period between 2024 and 2034? What are the implications of retinal gene therapy projects taking place now and over the next 10 years?
  • Is there a greater need for product commercialisation to further scale the Retinal Gene Therapy market?
  • Where is the retinal gene therapy market heading and how can you ensure you are at the forefront of the market?
  • What are the best investment options for new product and service lines?
  • What are the key prospects for moving companies into a new growth path and C-suite?
You need to discover how this will impact the Retinal Gene Therapy market today, and over the next 10 years:
  • Our 235-page report provides 99 tables and 160 charts/graphs exclusively to you.
  • The report highlights key lucrative areas in the industry so you can target them – NOW.
  • It contains in-depth analysis of global, regional and national sales and growth.
  • It highlights for you the key successful trends, changes and revenue projections made by your competitors.
Forecasts to 2034 and other analyses reveal commercial prospects
  • In addition to revenue forecasting to 2034, our new study provides you with recent results, growth rates, and market shares.
  • You will find original analyses, with business outlooks and developments.
  • Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising Retinal Gene Therapy prices and recent developments.
Segments Covered in the Report

Approach
  • Gene Replacement
  • Gene Silencing
  • Gene Editing
  • Modifier Gene Therapy
  • Others
Gene Therapy Vectors
  • Viral Vectors
  • Non-viral Vectors
Route of Administration
  • Invasive
  • Non-invasive
Indication
  • Leber Congenital Amaurosis (LCA)
  • Stargardt Disease
  • Choroideremia
  • X-linked Retinitis Pigmentosa (RP)
  • Others
End-users
  • Hospitals
  • Academic & Research Institutes
  • Ophthalmic Clinics
  • Others
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 22 leading national markets:

North America
  • U.S.
  • Canada
Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Russia
  • Rest of Europe
Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Indonesia
  • Rest of Asia Pacific
Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
MEA
  • GCC
  • South Africa
  • Rest of MEA
The report also includes profiles for some of the leading companies in the Retinal Gene Therapy Market, 2024 to 2034, with a focus on this segment of these companies’ operations.

Leading companies profiled in the report
  • AbbVie Inc.
  • Adverum Biotechnologies, Inc.
  • Beacon Therapeutics
  • GenSight Biologics S.A.
  • Hemera Biosciences LLC
  • MeiraGTx Limited
  • Novartis AG
  • Oxford Biomedica PLC
  • Oxular Limited
  • PulseSight Therapeutics
  • REGENXBIO Inc.
  • Spark Therapeutics
Overall world revenue for Retinal Gene Therapy Market, 2024 to 2034 in terms of value the market will surpass US$110.0 million in 2024, our work calculates. We predict strong revenue growth through to 2034. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Retinal Gene Therapy Market, 2024 to 2034 report help you?

In summary, our 230+ page report provides you with the following knowledge:
  • Revenue forecasts to 2034 for Retinal Gene Therapy Market, 2024 to 2034, with forecasts for approach, gene therapy vectors, ocular route of administration, indication (global), end user, and company size, each forecast at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.
  • Revenue forecasts to 2034 for five regional and 22 key national markets – See forecasts for the Retinal Gene Therapy Market, 2024 to 2034 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
  • Prospects for established firms and those seeking to enter the market – including company profiles for 12 of the major companies involved in the Retinal Gene Therapy Market, 2024 to 2034.
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else

With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Retinal Gene Therapy Market, 2024 to 2034, market-leading companies. You will find data, trends and predictions.

Please Note: Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.

The publisher is using a password system to access all reports. Single user (non-printable) and departmental licenses expires after 12 month period. In the case of departmental site license purchases, the publisher requires all email addresses for the licensed users prior to fulfillment.

Table of Contents

235 Pages
1 Report Overview
1.1 Objectives of the Study
1.2 Introduction to Retinal Gene Therapy Market
1.3 What This Report Delivers
1.4 Why You Should Read This Report
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report for?
1.7 Methodology
1.7.1 Market Definitions
1.7.2 Market Evaluation & Forecasting Methodology
1.7.3 Data Validation
1.7.3.1 Primary Research
1.7.3.2 Secondary Research
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Visiongain Reports
1.10 About Visiongain
2 Executive Summary
3 Market Overview
3.1 Key Findings
3.2 Market Dynamics
3.3 Impact Analysis
3.3.1 Market Driving Factors
3.3.1.1 Increasing Prevalence of Inherited Retinal Diseases (IRDs)
3.3.1.2 Advancements in Gene Therapy Technologies
3.3.1.3 Clinical Success and Regulatory Approvals
3.3.1.4 Growing Investment and Funding
3.3.2 Market Restraining Factors
3.3.2.1 Safety Concerns
3.3.2.2 Limited Treatment Reach
3.3.2.3 Long-Term Efficacy and Durability
3.3.2.4 High Cost of Treatment
3.3.2.5 Regulatory Challenges
3.3.3 Market Opportunities
3.3.3.1 Diversification of Targeted Diseases
3.3.3.2 Combination Therapies
3.3.3.3 Precision Medicine Approaches
3.3.3.4 Gene Editing Technologies
3.4 Porter’s Five Forces Analysis
3.4.1 Bargaining Power of Suppliers
3.4.2 Bargaining Power of Buyers
3.4.3 Competitive Rivalry
3.4.4 Threat from Substitutes
3.4.5 Threat of New Entrants
3.5 PEST Analysis
3.6 Pricing Analysis
3.7 Patient Data
3.8 Regulatory Framework
3.9 Emerging Markets and Megatrends
4 Retinal Gene Therapy Market Analysis by Approach
4.1 Key Findings
4.2 Retinal Gene Therapy Market Size Estimation and Forecast by Approach
4.3 Gene Replacement
4.3.1 Gene Replacement by Region, 2024-2034 (%)
4.3.2 Gene Replacement Market Share by Region, 2024 & 2034 (%)
4.4 Gene Silencing
4.4.1 Gene Silencing by Region, 2024-2034 (%)
4.4.2 Gene Silencing Market Share by Region, 2024 & 2034 (%)
4.5 Gene Editing
4.5.1 Gene Editing by Region, 2024-2034 (US$ Million)
4.5.2 Gene Editing Market Share by Region, 2024 & 2034 (%)
4.6 Modifier Gene Therapy
4.6.1 Modifier Gene Therapy by Region, 2024-2034 (US$ Million)
4.6.2 Modifier Gene Therapy Market Share by Region, 2024 & 2034 (%)
4.7 Others (Approach)
4.7.1 Others (Approach) by Region, 2024-2034 (US$ Million)
4.7.2 Others (Approach) Market Share by Region, 2024 & 2034 (%)
5 Retinal Gene Therapy Market Analysis by Gene Therapy Vectors
5.1 Key Findings
5.2 Gene Therapy Vectors: Market Attractiveness Index
5.3 Retinal Gene Therapy Market Size Estimation and Forecast by Gene Therapy Vectors
5.4 Viral Vectors
5.4.1 Viral Vectors Market Size by Region, 2024-2034 (US$ Million)
5.4.2 Viral Vectors Market Share by Region, 2024 & 2034 (%)
5.5 Non-viral Vectors
5.5.1 Non-viral Vectors Market Size by Region, 2024-2034 (US$ Million)
5.5.2 Non-viral Vectors Market Share by Region, 2024 & 2034 (%)
6 Retinal Gene Therapy Market Analysis by Route of Administration
6.1 Key Findings
6.2 Route of Administration: Market Attractiveness Index
6.3 Retinal Gene Therapy Market Size Estimation and Forecast by Route of Administration
6.4 Invasive
6.4.1 Invasive Market Size by Region, 2024-2034 (US$ Million)
6.4.2 Invasive Market Share by Region, 2024 & 2034 (%)
6.5 Non-invasive
6.5.1 Non-invasive Market Size by Region, 2024-2034 (US$ Million)
6.5.2 Non-invasive Market Share by Region, 2024 & 2034 (%)
7 Retinal Gene Therapy Market Analysis: By Indication
7.1 Key Findings
7.2 Indication Segment: Market Attractiveness Index
7.3 Retinal Gene Therapy Market Size Estimation and Forecast by Indication
7.4 Leber Congenital Amaurosis (LCA)
7.5 Stargardt Disease
7.6 Choroideremia
7.7 X-linked Retinitis Pigmentosa (RP)
7.8 Others
8 Retinal Gene Therapy Market Analysis: End-users
8.1 Key Findings
8.2 End-users Segment: Market Attractiveness Index
8.3 Retinal Gene Therapy Market Segment Size Estimation and Forecast by End-users
8.4 Hospitals
8.4.1 Hospital Market Size by Region, 2024-2034 (US$ Million)
8.4.2 Hospitals Market Share by Region, 2024 & 2034 (%)
8.5 Academic & Research Institutes
8.5.1 Academic & Research Market Size by Region, 2024-2034 (US$ Million)
8.5.2 Academic & Research Institutes Market Share by Region, 2024 & 2034 (%)
8.6 Ophthalmic Clinics
8.6.1 Ophthalmic Clinics Market Size by Region, 2024-2034 (US$ Million)
8.6.2 Ophthalmic Clinics Market Share by Region, 2024 & 2034 (%)
8.7 Others
8.7.1 Others Market Size by Region, 2024-2034 (US$ Million)
8.7.2 Other Market Share by Region, 2024 & 2034 (%)
9 Retinal Gene Therapy Market Analysis by Region
9.1 Key Findings
9.2 Retinal Gene Therapy by Region: Market Attractiveness Index
9.3 Regional Market Size Estimation and Forecast
10 North America Retinal Gene Therapy Market Analysis
10.1 Key Findings
10.2 North America Retinal Gene Therapy Market Attractiveness Index
10.3 North America Retinal Gene Therapy Market by Country, 2024, 2029 & 2034 (US$ Million)
10.4 North America Retinal Gene Therapy Market Size Estimation and Forecast by Country
10.5 North America Retinal Gene Therapy Market Size Estimation and Forecast by Approach
10.6 North America Retinal Gene Therapy Market Size Estimation and Forecast by Gene Therapy Vectors
10.7 North America Retinal Gene Therapy Market Size Estimation and Forecast by Route of Administration
10.8 North America Retinal Gene Therapy Market Size Estimation and Forecast by End-users
10.9 U.S. Retinal Gene Therapy Market Analysis
10.10 Canada Retinal Gene Therapy Market Analysis
11 Europe Retinal Gene Therapy Market Analysis
11.1 Key Findings
11.2 Europe Retinal Gene Therapy Market Attractiveness Index
11.3 Europe Retinal Gene Therapy Market by Country, 2024, 2029 & 2034 (US$ Million)
11.4 Europe Retinal Gene Therapy Market Size Estimation and Forecast by Country
11.5 Europe Retinal Gene Therapy Market Size Estimation and Forecast by Approach
11.6 Europe Retinal Gene Therapy Market Size Estimation and Forecast by Gene Therapy Vectors
11.7 Europe Retinal Gene Therapy Market Size Estimation and Forecast by Route of Administration
11.8 Europe Retinal Gene Therapy Market Size Estimation and Forecast by End-users
11.9 Germany Retinal Gene Therapy Market Analysis
11.10 France Retinal Gene Therapy Market Analysis
11.11 UK Retinal Gene Therapy Market Analysis
11.12 Italy Retinal Gene Therapy Market Analysis
11.13 Spain Retinal Gene Therapy Market Analysis
11.14 Russia Retinal Gene Therapy Market Analysis
11.15 Rest of Europe Retinal Gene Therapy Market Analysis
12 Asia Pacific Retinal Gene Therapy Market Analysis
12.1 Key Findings
12.2 Asia Pacific Retinal Gene Therapy Market Attractiveness Index
12.3 Asia Pacific Retinal Gene Therapy Market by Country, 2024, 2029 & 2034 (US$ Million)
12.4 Asia Pacific Retinal Gene Therapy Market Size Estimation and Forecast by Country
12.5 Asia Pacific Retinal Gene Therapy Market Size Estimation and Forecast by Approach
12.6 Asia Pacific Retinal Gene Therapy Market Size Estimation and Forecast by Gene Therapy Vectors
12.7 Asia Pacific Retinal Gene Therapy Market Size Estimation and Forecast by Route of Administration
12.8 Asia Pacific Retinal Gene Therapy Market Size Estimation and Forecast by End-users
12.9 Japan Retinal Gene Therapy Market Analysis
12.10 China Retinal Gene Therapy Market Analysis
12.11 India Retinal Gene Therapy Market Analysis
12.12 Australia Retinal Gene Therapy Market Analysis
12.13 South Korea Retinal Gene Therapy Market Analysis
12.14 Indonesia Retinal Gene Therapy Market Analysis
12.15 Rest of Asia Pacific Retinal Gene Therapy Market Analysis
13 Latin America Retinal Gene Therapy Market Analysis
13.1 Key Findings
13.2 Latin America Retinal Gene Therapy Market Attractiveness Index
13.3 Latin America Retinal Gene Therapy Market by Country, 2024, 2029 & 2034 (US$ Million)
13.4 Latin America Retinal Gene Therapy Market Size Estimation and Forecast by Country
13.5 Latin America Retinal Gene Therapy Market Size Estimation and Forecast by Approach
13.6 Latin America Retinal Gene Therapy Market Size Estimation and Forecast by Gene Therapy Vectors
13.7 Latin America Retinal Gene Therapy Market Size Estimation and Forecast by Route of Administration
13.8 Latin America Retinal Gene Therapy Market Size Estimation and Forecast by End-users
13.9 Brazil Retinal Gene Therapy Market Analysis
13.10 Mexico Retinal Gene Therapy Market Analysis
13.11 Rest of Latin America Retinal Gene Therapy Market Analysis
14 MEA Retinal Gene Therapy Market Analysis
14.1 Key Findings
14.2 MEA Retinal Gene Therapy Market Attractiveness Index
14.3 MEA Retinal Gene Therapy Market by Country, 2024, 2029 & 2034 (US$ Million)
14.4 MEA Retinal Gene Therapy Market Size Estimation and Forecast by Country
14.5 MEA Retinal Gene Therapy Market Size Estimation and Forecast by Approach
14.6 MEA Retinal Gene Therapy Market Size Estimation and Forecast by Gene Therapy Vectors
14.7 MEA Retinal Gene Therapy Market Size Estimation and Forecast by Route of Administration
14.8 MEA Retinal Gene Therapy Market Size Estimation and Forecast by End-users
14.9 GCC Retinal Gene Therapy Market Analysis
14.10 South Africa Retinal Gene Therapy Market Analysis
14.11 Rest of MEA Retinal Gene Therapy Market Analysis
15 Company Profiles
15.1 Competitive Landscape, 2023
15.2 Strategic Outlook
15.3 Novartis AG
15.3.1 Company Snapshot
15.3.2 Company Overview
15.3.3 Financial Analysis
15.3.3.1 Net Revenue, 2019-2023
15.3.3.2 R&D, 2019-2023
15.3.3.3 Regional Market Shares, 2023
15.3.4 Product Benchmarking
15.3.5 Strategic Outlook
15.3.6 SWOT Analysis
15.4 Beacon Therapeutics
15.4.1 Company Snapshot
15.4.2 Company Overview
15.4.3 Product Benchmarking
15.4.4 Clinical Trials
15.4.5 Strategic Outlook
15.4.6 SWOT Analysis
15.5 Spark Therapeutics
15.5.1 Company Snapshot
15.5.2 Company Overview
15.5.3 Product Benchmarking
15.5.4 Clinical Trials
15.5.5 Strategic Outlook
15.5.6 SWOT Analysis
15.6 Adverum Biotechnologies, Inc.
15.6.1 Company Snapshot
15.6.2 Company Overview
15.6.3 Product Benchmarking
15.6.4 Clinical Trials
15.6.5 SWOT Analysis
15.7 REGENXBIO Inc.
15.7.1 Company Snapshot
15.7.2 Company Overview
15.7.3 Financial Analysis
15.7.3.1 Net Revenue, 2018-2023
15.7.3.2 R&D, 2018-2023
15.7.4 Product Benchmarking
15.7.5 Clinical Trials
15.7.6 SWOT Analysis
15.8 MeiraGTx Limited
15.8.1 Company Snapshot
15.8.2 Company Overview
15.8.3 Financial Analysis
15.8.3.1 Net Revenue, 2018-2023
15.8.3.2 R&D, 2018-2023
15.8.4 Clinical Trials
15.8.5 SWOT Analysis
15.9 GenSight Biologics
15.9.1 Company Snapshot
15.9.2 Company Overview
15.9.3 Financial Analysis
15.9.3.1 Net Revenue, 2020-2023
15.9.3.2 R&D, 2020-2023
15.9.4 Clinical Trials
15.9.5 SWOT Analysis
15.10 AbbVie Inc.
15.10.1 Company Snapshot
15.10.2 Company Overview
15.10.3 Financial Analysis
15.10.3.1 Net Revenue, 2018-2023
15.10.3.2 R&D, 2018-2023
15.10.4 Clinical Trials
15.10.5 SWOT Analysis
15.11 Oxular Limited
15.11.1 Company Snapshot
15.11.2 Company Overview
15.11.3 Clinical Trials
15.12 PulseSight Therapeutics
15.12.1 Company Snapshot
15.12.2 Company Overview
15.12.3 Clinical Trials
15.12.4 SWOT Analysis
15.13 Oxford Biomedica PLC
15.13.1 Company Snapshot
15.13.2 Company Overview
15.13.3 Financial Analysis
15.13.3.1 Net Revenue, 2019-2023
15.13.4 Product Benchmarking
15.13.5 SWOT Analysis
15.14 Hemera Biosciences LLC
15.14.1 Company Snapshot
15.14.2 Company Overview
15.14.3 Clinical Trials
16 Conclusion and Recommendations
16.1 Concluding Remarks from Visiongain
16.2 Recommendations for Market Players

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us